ClinicalTrials.gg
CompletedNCT05797896i-GAINUpdated Oct 28, 2026

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

An observational study in Dry Age-related Macular Degeneration, Geographic Atrophy and Retinal Disease, sponsored by Complement Therapeutics. Completed at 22 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Complement Therapeutics · Observational

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
234
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Geographic Atrophy with a site in United Kingdom — 13 open to participants now, 17 under way, 4 of them phase 3. Geographic Atrophy · United Kingdom.

Started
2023
with 2 others
Observational
8 of 38
3 open now
Registered
23rd of 38
by date
Lead sponsor
3 of 38
Complement Therapeutics

Among the 38 studies in Geographic Atrophy with a site in United Kingdom, this one is one of 3 that started in 2023, is one of 8 observational ones, and was the 23rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

13 of the 38 studies in Geographic Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 65 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Geographic Atrophy with a site in United Kingdom, or all of them as a file.
02

Study summary

An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration

Read the detailed description

Prospective, observational study to assess the relationships between circulating levels of complement proteins measured using the Complement Precision Medicine (CPM) Platform, genetic profile and lesion progression in subjects with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD) up to a 24-month period

03

Conditions studied

  • Dry Age-related Macular Degeneration
  • Geographic Atrophy
  • Retinal Disease
  • Macular Degeneration
  • Macular Atrophy
  • Retinal Degeneration
  • Eye Diseases

Keywords

  • Dry Age-related Macular Degeneration
  • Geographic Atrophy
  • Retinal Disease
  • Macular Degeneration
  • Macular Atrophy
  • Retinal Degeneration
  • Eye Diseases
  • AMD
  • GA
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Approximately 250 participants, age 65 years and older, with bilateral GA due to AMD will be accrued.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of bilateral GA due to AMD as confirmed by fundoscopy and imaging at Screening
  2. GA lesion sizes of ≥ 1.25 mm2 to ≤ 17 mm2 (approximately 1-7 disc diameters) in at least one eye as per Central Reading Center
  3. Willing and able to provide written
  4. Male or female aged 65 years and over

Exclusion criteria

Exclusion Criteria:

  1. History of neovascular (wet) AMD or presence of neovascular (wet) AMD in either eye confirmed by fundoscopy at screening and/or any pre-existing retinal imaging
  2. History of intravitreal (IVT) injection in the study eye. Note: Intravitreal treatment with pegcetacoplan (Syfovre®) and avacincaptad pegol (IzervayTM) if approved within the participant's country of origin AND if deemed necessary by the Principal Investigator (PI) is allowed in the fellow eye only. IVT injections in the study eye are prohibited.
  3. History of uveitis or endophthalmitis
  4. High myopia (more than 6 diopter) in the study eye
  5. Any ocular pathology which would impede clear imaging of the macula, e.g. intra-ocular opacities
  6. Macular changes from causes other than AMD
  7. Diabetic retinopathy in either eye. Note: Presence of systemic diabetes with no retinopathy is not exclusionary
  8. Any other physical condition which would prevent the participant from undertaking imaging procedures
  9. Any cell or gene therapy in either eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
234 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Levels of complement proteins

    To assess the correlation between circulating levels of complement proteins measured using the Complement Precision Medicine (CPM) Platform and Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    Time frame: Month 6, 12,18, 24

Secondary outcomes

  1. Geographic Atrophy

    To investigate whether there is a relationship between progression of GA and complement profile measured using the CPM platform

    Time frame: Up to 24 months

  2. Genetics

    To investigate the relationship between variants in genes or loci associated with AMD and the complement profile measured using the CPM platform

    Time frame: Up to 24 months

  3. Complement Proteins Intra-individual Variation

    To determine the intra-individual variation in complement profile using the Complement Precision Medicine (CPM) Platform, in participants with GA

    Time frame: Up to 24 months

  4. Complement Proteins and Progression of GA

    To investigate whether there is a relationship between progression of GA and complement profile measured using the Complement Precision Medicine (CPM) platform

    Time frame: Up to 24 months

  5. Choroidal Blood Flow and Genetics

    To investigate the relationship in genes or loci associated with AMD and choroidal blood flow and structure

    Time frame: Up to 24 months

  6. Choroidal Blood Flow and GA Lesion Progression

    To investigate the relationships between choroidal blood flow and structure and GA lesion progression

    Time frame: Up to 24 months

  7. CRP Levels

    To observe the influence of any past or concurrent illnesses, in particular inflammation-related illnesses, rise in serum CRP or of any medications on complement profile using the CPM Platform

    Time frame: Up to 24 months

07

Study locations

22 sites
  • Global Research Management
    Glendale, California 91204, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Midwest Eye Institute
    Carmel, Indiana 46290, United States
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
  • Sierra Eye Associates
    Reno, Nevada 89506, United States
  • Verum Research LLC
    Eugene, Oregon 97401, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19610, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Texas Retina Associates
    Plano, Texas 75075, United States
  • San Antonio Eye Center
    San Antonio, Texas 78215, United States
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Bradford Royal Infirmary
    Bradford, BD9 6TB, United Kingdom
  • Frimley Park Hospital
    Frimley, GU16 7UJ, United Kingdom
  • Gloucestershire Royal Hospital
    Gloucester, GL1 3NN, United Kingdom
  • Liverpool Hospital
    Liverpool, L7 8XP, United Kingdom
  • Moorfields Eye Hospital
    London, EC1V 2PD, United Kingdom
  • Western Eye Hospital
    London, NW1 5QH, United Kingdom
  • Manchester Royal Eye Hospital
    Manchester, M13 9WL, United Kingdom
  • Newcastle Hospital
    Newcastle, NE1 4LP, United Kingdom
  • Nottingham City Hospital
    Nottingham, NG7 2UH, United Kingdom
  • University Hospital Southampton
    Southampton, SO16 6YD, United Kingdom
  • Sunderland Eye Infirmary
    Sunderland, SR2 9HP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2023 to primary completion in Dec 2025, 34 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jul 2027 → Dec 2025 and completion Jul 2027 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 4, 2023
StartActual
Feb 7, 2023
Primary completionActual
Dec 11, 2025was Jul 2027
CompletionActual
Dec 11, 2025was Jul 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Primary completion
Jul 31, 2027→Dec 11, 2025 (actual)
Oct 28, 2026
Study completion
Jul 31, 2027→Dec 11, 2025 (actual)
Oct 28, 2026
Enrollment
250 (estimated)→234 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    Primary completion Jul 31, 2027→Dec 11, 2025 (now actual)
    Study completion Jul 31, 2027→Dec 11, 2025 (now actual)
    Enrollment 250 (estimated)→234 (actual)
    + 4 other changes: verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05797896
Lead sponsor
Complement Therapeutics
Responsible party
Sponsor
First posted
Apr 4, 2023
Start date
Feb 7, 2023
Primary completion
Dec 11, 2025
Completion
Dec 11, 2025
Last update
Oct 28, 2026

Study contacts

Marta Ugarte
principal investigator · Manchester Royal Eye Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion